AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20708634
Drug: Non-carriers (L/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-carriers (L/L genotype)
Trial: 20708634
Drug: L/S genotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/S genotype
Trial: 8398959
Drug: 45 ml
RxNorm normalized name: ethanol 0.645 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 ml interscalene brachial plexus block with 1.5% mepivacaine, epinephrine, and bicarbonate
Trial: 8398959
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml interscalene brachial plexus block with 1.5% mepivacaine, epinephrine, and bicarbonate
Trial: 29781549
Drug: Platelets administered
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelets administered before transport to surgery
Trial: 27842532
Drug: Silybin 94
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg
Trial: 20562409
Drug: One-visit root
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit root canal therapy (ORCT), n = 202
Trial: 20652790
Drug: One-visit root
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit root canal therapy (ORCT)
Trial: 16398773
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg self-administered vaginal misoprostol
Trial: 12927624
Drug: Alfentanil (4.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (4.1 +/- 0.5 mg) administered for 90 min
Trial: 10807893
Drug: 1.5 kcal/ml
RxNorm normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 kcal/ml nutritional supplement
Trial: 6736345
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with 2% crude coal tar ointment
Trial: 31887854
Drug: Rivastigmine patch
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine patch (10 cm² = 9.5 mg)
Trial: 25670764
Drug: pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin (30 mg/m²) followed by carboplatin (AUC 5 mg min/ml) every 28 days
Trial: 21668741
Drug: Butorphanol (0.016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (0.016 mg/kg)
Trial: 17005060
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (directed cough)
Trial: 12024755
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ARD and CHX rinse
Trial: 9263319
Drug: Hydrocortisone 2.5%
RxNorm normalized name: HYDROCORTISONE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 2.5% cream once daily + water-in-oil cream once daily
Trial: 9263319
Drug: Hydrocortisone 2.5%
RxNorm normalized name: HYDROCORTISONE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 2.5% cream twice daily
Trial: 8500857
Drug: KCl infusions
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl infusions (0.12 and 0.24 mEq/min) with ouabain (2 micrograms/min)
Trial: 8500857
Drug: KCl infusions
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KCl infusions (0.12 and 0.24 mEq/min) after salt loading (180 mEq NaCl for 7 days)
Trial: 27410923
Drug: Ipilimumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (both doses)
Trial: 19903780
Drug: GM-CSF (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF (110 microg) with multipeptide vaccine
Trial: 19903780
Drug: Multipeptide vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multipeptide vaccine without GM-CSF
Trial: 19903780
Drug: Multipeptide vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multipeptide vaccine with GM-CSF
Trial: 16518754
Drug: Pegylated IFN‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated IFN‐alpha 2a and ribavirin combination therapy
Trial: 12184546
Drug: Active vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitamin D treatment (VD(+))
Trial: 12184546
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (VD(-))
Trial: 2801579
Drug: Protein diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein diet (400 kcal/d, 13.2 g nitrogen, 23 mmol potassium)
Trial: 2801579
Drug: Glucose diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose diet (400 kcal/d, 16 mmol potassium chloride, multivitamin supplement)
Trial: 1102148
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate aerosol (100 mug into each nostril twice daily)
Trial: 31516032
Drug: Glasdegib 100
RxNorm normalized name: glasdegib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg once daily plus low-dose cytarabine
Trial: 23432600
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (20 mg of omeprazole, 500 mg of clarithromycin, and 1000 mg of amoxicillin orally two times daily)
Trial: 21310819
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1ra) for 4 weeks
Trial: 19583746
Drug: Physostigmine (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (1.8 mg)
Trial: 17179269
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 20 mL of 0.375% levobupivacaine
Trial: 30172099
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg daily oral edoxaban
Trial: 30172099
Drug: VKA-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA-based therapy (international normalized ratio: 2.0-3.0 or 1.6-2.6 in Japan if age ≥ 70 years)
Trial: 30172099
Drug: Both edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both edoxaban and VKA-based therapy
Trial: 22727160
Drug: Salmeterol-fluticasone (50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol-fluticasone (50/100 μg twice daily)
Trial: 22727160
Drug: Fluticasone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (100 μg twice daily)
Trial: 19719551
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta-estradiol + 10 mg dydrogesterone
Trial: 19719551
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17beta-estradiol + 10 mg dydrogesterone
Trial: 12811706
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of nasal sumatriptan
Trial: 12811706
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of intravenous ketorolac
Trial: 7084138
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral and written information
Trial: 8646433
Drug: Naloxone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (20 mg i.v. infusion)
Trial: 8646433
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (RA and controls) after naloxone treatment
Trial: 8646433
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (RA and controls) after any treatment
Trial: 6337421
Drug: Cephalexin, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin, 250 mg every six hours for 72 hours
Trial: 30004561
Drug: Conventional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional surgical treatment with posterior approach (Control)
Trial: 23131066
Drug: High-rate therapy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-rate therapy (2.5-second delay at heart rate ≥200 bpm)
Trial: 23131066
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy (60-second delay at 170-199 bpm, 12-second delay at 200-249 bpm, 2.5-second delay at ≥250 bpm)
Trial: 18490498
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin delta
Trial: 16283958
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of 2% lidocaine
Trial: 16283958
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of 0.5% bupivacaine
Trial: 16283958
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of 2% lidocaine and 15 mg of 0.5% bupivacaine
Trial: 12467943
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg meta-chlorophenylpiperazine (MCPP)
Trial: 9503255
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ipsapirone
Trial: 10342343
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg per day for 4 months
Trial: 7141761
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) pretreatment (p.o. 5.0 g/24 h)
Trial: 7141761
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (1.0 or 1.5 g orally)
Trial: 7141761
Drug: Pindolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (1 mg i.v.)
Trial: 22370834
Drug: Neural mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neural mobilization treatment
Trial: 18679605
Drug: Dihuang Zhixue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihuang Zhixue Capsule (DZC), 2 to 3 capsules orally, thrice a day for 3 months
Trial: 18679605
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA), 3 mg/kg per day for 3 months
Trial: 18679605
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after 2 months treatment
Trial: 18679605
Drug: After 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 3 months treatment
Trial: 18679605
Drug: After 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 8 weeks treatment
Trial: 14506391
Drug: Pre-S2/S HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-S2/S HBV vaccine (GenHevac-B) 20 micro g, 3 intramuscular injections on days 0, 30, and 60
Trial: 9391135
Drug: cp‐52 (cold-passaged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cp‐52 (cold-passaged candidate vaccine virus)
Trial: 8459987
Drug: Ondansetron (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (32 mg i.v. single dose/day) plus dexamethasone (20 mg i.v. single dose/day)
Trial: 8459987
Drug: Metoclopramide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2 mg/kg or 1 mg/kg i.v. twice a day) plus dexamethasone (20 mg i.v. single dose/day)
Trial: 1279169
Drug: Intravenous iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous iloprost
Trial: 29261568
Drug: Thrombin activatable
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombin activatable fibrinolysis inhibitor level and in vivo markers of fibrinolysis activation (plasmin‐antiplasmin complex, D‐dimer).
Trial: 10417499
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg) plus Cimetidine (400 mg)
Trial: 7648219
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (specific classes not mentioned)
Trial: 2134115
Drug: Minaprine (200-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine (200-300 mg daily)
Trial: 2134115
Drug: Amitriptyline (50-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50-75 mg daily)
Trial: 7004723
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of moderate salt restriction and high potassium intake (from 80 to 200 mmol/day)
Trial: 22231174
Drug: Subcutaneous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous unfractionated heparin (SQH), 5,000 units subcutaneously three times daily
Trial: 22231174
Drug: Intravenous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous unfractionated heparin (IVH), titrated to an activated partial thromboplastin time of 40-45 s
Trial: 17647293
Drug: Clevudine 30
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clevudine 30 mg daily for 24 weeks
Trial: 17102823
Drug: Postoperative craniospinal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative craniospinal radiation therapy (36Gy+boost 20Gy to the posterior fossa)
Trial: 17102823
Drug: Postoperative combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative combination cranio-spinal radiation therapy (same dose as group I) and chemotherapy (vincristine, etoposide, cisplatin)
Trial: 17102823
Drug: Postoperative craniospinal
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative craniospinal radiation therapy (group I)
Trial: 17102823
Drug: Postoperative combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative combination cranio-spinal radiation therapy and chemotherapy (group II)
Trial: 12195129
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/day (titrated to 100 mg/day)
Trial: 12195129
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg/day (titrated to 100 mg/day)
Trial: 2198294
Drug: Pentobarbital (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (100, 200, and 300 mg)
Trial: 28294080
Drug: Bilateral sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral sequential same-day tympanoplasty
Trial: 24220392
Drug: Intra-articular injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injections of high-molecular-weight hyaluronic acid (HA)
Trial: 21698811
Drug: Alverina citrate
RxNorm normalized name: alverine
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alverina citrate 60 mg with Simethicone 300 mg three times daily
Trial: 21698811
Drug: Alverina citrate
RxNorm normalized name: alverine
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alverina citrate and Simethicone combination
Trial: 19233855
Drug: Dual-antiplatelet agents
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-antiplatelet agents with highest tertile aspirin dose
Trial: 15303131
Drug: Group G+E
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G+E (epidural anesthesia combined with general anesthesia)
Trial: 15303131
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G (general anesthesia)
Trial: 15303131
Drug: Group G+E
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G+E and Group G
Trial: 15303131
Drug: Groups G+E
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups G+E and G
Trial: 15303131
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G and Group G+E
Trial: 11772119
Drug: Tianeptine (12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (12.5mg three times daily)
Trial: 11772119
Drug: Paroxetine (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20mg once daily plus two placebo capsules)
Trial: 30165844
Drug: Once-weekly injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly injection of exenatide
Trial: 30165844
Drug: Twice-daily injection
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily injection of exenatide
Trial: 20937187
Drug: Generic 3-drug
RxNorm normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic 3-drug fixed-dose combination (3FDC) formulation of rifampicin
Trial: 18782787
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standardized perioperative therapy without fenoldopam)
Trial: 11952069
Drug: Continuous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous midazolam infusion (n = 21)
Trial: 11952069
Drug: Diazepam infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam infusion (n = 19)
Trial: 7723546
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus antibody 33B3.1 (n = 51)
Trial: 1952306
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg methotrimeprazine (Levoprome, Nozinan)
Trial: 1952306
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg meperidine (Demerol) combined with 50 mg dimenhydrinate (Dramamine, Gravol)
Trial: 9278199
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg three times daily)
Trial: 22849762
Drug: Moogoo Udder
RxNorm normalized name: Corona Udder Butter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moogoo Udder Cream®
Trial: 17545739
Drug: memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine (20 mg/d)
Trial: 15887425
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg/d) added to ongoing statin therapy
Trial: 15887425
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ongoing statin therapy
Trial: 7908877
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium cromoglycate solution and oral oxatomide
Trial: 7908877
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo solution and oral oxatomide
Trial: 1831397
Drug: High-dose medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose medroxyprogesterone acetate (MPA)
Trial: 2970555
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) and High-dose medroxyprogesterone acetate (MPA)
Trial: 28154369
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment consistent with the guidelines for AP
Trial: 19233339
Drug: Attention-based rehearsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-based rehearsal (not specified in dosage or duration)
Trial: 19233339
Drug: Facilitation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitation of processing at the memorized location (not specified in dosage or duration)
Trial: 17118191
Drug: Micronutrient mix
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient mix (288 mg vitamin E, 375 mg vitamin C, 12 mg beta-carotene, 15 mg zinc/day)
Trial: 17118191
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum concentrate (1.2 g/d)
Trial: 17118191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of colostrum and micronutrient mix
Trial: 8612408
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion continued